Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 17/20 | 0.72 |
| ▸ | FLT1 | P17948 | 13/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.72 |
| ▸ | KIT | P10721 | 3/20 | 0.72 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | FLT4 | P35916 | 2/20 | 0.72 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | HLA-A | P04439 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | FRK | P42685 | 1/20 | 0.57 |
| ▸ | CDK8 | P49336 | 1/20 | 0.57 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.57 |
| ▸ | STK3 | Q13188 | 1/20 | 0.57 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.57 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.57 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.57 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5684075 | 0.91 | KDR (0.76) | KDRFLT1PDGFRBKITCSF1R | |
| Hydrochloric Acid SCHEMBL4257772 | 0.90 | KDR (0.74) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL1685425 | 0.84 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL675786 | 0.84 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL19639128 | 0.84 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL5154569 | 0.79 | KDR (0.89) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL6608914 | 0.79 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.77 | KDR (0.88) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6053178 | 0.77 | FLT1 (0.69) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL6600324 | 0.74 | KDR (0.71) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123580-A1 | Combination of histone deacetylase inhibitors with chemotherapeutic agents | ATADJA PETER W | 2007-05-31 | — | — | US | claimed |
| EP-1628651-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | Novartis AG (CH) | 2006-03-01 | — | — | EP | claimed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | claimed |
| US-20070123580-A1 | Combination of histone deacetylase inhibitors with chemotherapeutic agents | ATADJA PETER W | 2007-05-31 | — | — | US | disclosed |
| EP-1682181-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1628651-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | Novartis AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005027972-A2 | COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123580-A1 | Combination of histone deacetylase inhibitors with chemotherapeutic agents | HDAC1, HDAC9, HDAC5 | EGFR 3667/4885KDR 4722/4885FLT1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.